• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 20-F filed by Cuprina Holdings (Cayman) Limited

    4/17/25 7:33:24 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CUPR alert in real time by email
    NT 20-F 1 formnt20-f.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    (Check one):   ☐ Form 10-K ☒ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR
       
        For Period Ended: December 31, 2024
       
        ☐ Transition Report on Form 10-K
       
        ☐ Transition Report on Form 20-F
       
        ☐ Transition Report on Form 11-K
       
        ☐ Transition Report on Form 10-Q
       
        For the Transition Period Ended: _________________

     

    Nothing in this form shall be construed to imply that the Commission has verified any information

    contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

    PART I - REGISTRANT INFORMATION

     

    Cuprina Holdings (Cayman) Limited

    Full Name of Registrant

    N/A

    Former Name if Applicable

     

    c/o Blk 1090 Lower Delta Road #06-08
    Singapore, 169201
    Address of Principal Executive Office (Street and Number)

     

    Singapore, 169201

    City, State and Zip Code

     

     

     

     

     

     

    PART II - RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

        (a)   The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

    ☒

      (b)   The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
        (c)   The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III - NARRATIVE

     

    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    Cuprina Holdings (Cayman) Limited (the “Company”) is unable to file, without unreasonable effort and expense, its annual report on Form 20-F for the fiscal year ended December 31, 2024 (the “Form 20-F”) because it requires additional time to finalize the Form 20-F. The Company plans to file the Form 20-F no later than the fifteenth calendar day after its prescribed due date.

     

    PART IV

    OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification

     

    David Quek Yong Qi   +65   8512 7275
    (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
    ☒ Yes ☐ No

     

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?
    ☐ Yes ☒ No

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively , and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     

     

     

    Cuprina Holdings (Cayman) Limited

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

     

      Cuprina Holdings (Cayman) Limited
       
      By: /s/ David Quek Yong Qi
      Name:  David Quek Yong Qi
      Title: Director and Chief Executive Officer

     

    Date: April 17, 2025

     

     

     

     

     

     

     

     

    Get the next $CUPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CUPR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CUPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cuprina Holdings (Cayman) Limited Announces Financial Results for the Six Months Ended June 30, 2025, and Strategic Initiatives for 2026 Growth

    SINGAPORE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today  announced its financial results for the six months ended June 30, 2025. "Although our revenue decreased and our net loss increased compared with the same period last year, the first six months of 2025 allowed us to achieve significant advances in both diversifying our product and technology portfolio and expanding our geographic footprint," said Cuprina Chief Executive Officer, Mr. David Quek Yong Qi. Diversification

    12/9/25 8:30:00 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cuprina Holdings (Cayman) Limited Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

    SINGAPORE, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, and cosmeceuticals sectors, today announced it has received a letter of noncompliance from The Nasdaq Stock Market LLC ("Nasdaq"), dated November 26, 2025, notifying the Company that based on Cuprina's closing bid price for the last 30 consecutive business days, the Company no longer meets the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share. However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A), th

    11/28/25 8:30:00 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cuprina Signs MOU with Singapore Biowaste Solutions to Integrate Medical Waste Management Technologies

    SINGAPORE, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, and cosmeceuticals sectors, today said it has signed a Memorandum of Understanding (MOU) with Singapore Biowaste Solutions Pte Ltd (SBS), a treater and disposer of bio-medical waste, to explore the integration of Cuprina's medical waste recycling technology into SBS's existing waste management facility in Singapore. The collaboration aims to develop an integrated process that will further reduce reliance on incineration and landfilling, enhance recycling efficiency, unlock new

    10/27/25 8:40:00 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUPR
    SEC Filings

    View All

    SEC Form 6-K filed by Cuprina Holdings (Cayman) Limited

    6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

    12/9/25 8:25:53 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Cuprina Holdings (Cayman) Limited

    6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

    11/28/25 8:30:31 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Cuprina Holdings (Cayman) Limited

    6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

    11/18/25 8:30:12 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CUPR
    Leadership Updates

    Live Leadership Updates

    View All

    Cuprina Appoints Dr. Ronald Sherman, Leader in Maggot Debridement Therapy, as Medical and Scientific Director; Secures FDA-approved Medical Maggot License for U.S. Market

    SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("CUPR" or "the Company"), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced that Dr. Ronald A. Sherman, a leading innovator in the use of medical maggots to treat chronic wounds, has agreed to join the Company as Medical and Scientific Director in September 2025. Cuprina also announced it has signed an agreement with Dr. Sherman licensing his 2004 FDA clearance to market Lucilia sericata Medical MaggotsTM, the first

    7/21/25 9:00:00 AM ET
    $CUPR
    Biotechnology: Pharmaceutical Preparations
    Health Care